Welcome to RxCell, a leading biotechnology company dedicated to advancing the frontiers of therapeutic applications through induced pluripotent stem cells (iPSC). At RxCell, we are driven by a passion for groundbreaking research, and our commitment is evident in our pioneering work in iPSC technology.

 

Our Core Focus: Retinal Cells derived from Therapeutic Grade iPSC Master Cell Banks

 

At the heart of our mission is the development of retinal progenitor cells derived from therapeutic-grade iPSC line master cell banks (MCB). These current good manufacture practice (cGMP) iPSC MCB serve as the foundation for our innovative endeavors. Currently, we are in the process of manufacturing retinal progenitor cells from one of our iPSC MCB for an IND (investigational new drug) application with the FDA, a pivotal step that underpins our ongoing and future therapeutic activities.